Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.67
OMER's Cash to Debt is ranked lower than
85% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. OMER: 0.67 )
Ranked among companies with meaningful Cash to Debt only.
OMER' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.21 Max: N/A
Current: 0.67
Equity to Asset -0.31
OMER's Equity to Asset is ranked lower than
96% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMER: -0.31 )
Ranked among companies with meaningful Equity to Asset only.
OMER' s Equity to Asset Range Over the Past 10 Years
Min: -15.24  Med: -0.26 Max: 0.7
Current: -0.31
-15.24
0.7
F-Score: 5
Z-Score: -6.70
M-Score: 2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -170.85
OMER's Operating margin (%) is ranked lower than
58% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. OMER: -170.85 )
Ranked among companies with meaningful Operating margin (%) only.
OMER' s Operating margin (%) Range Over the Past 10 Years
Min: -12988.5  Med: -1430.21 Max: -170.85
Current: -170.85
-12988.5
-170.85
Net-margin (%) -189.16
OMER's Net-margin (%) is ranked lower than
60% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. OMER: -189.16 )
Ranked among companies with meaningful Net-margin (%) only.
OMER' s Net-margin (%) Range Over the Past 10 Years
Min: -13668.46  Med: -1389.6 Max: -189.16
Current: -189.16
-13668.46
-189.16
ROA (%) -136.47
OMER's ROA (%) is ranked lower than
91% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. OMER: -136.47 )
Ranked among companies with meaningful ROA (%) only.
OMER' s ROA (%) Range Over the Past 10 Years
Min: -538.37  Med: -97.57 Max: -50.37
Current: -136.47
-538.37
-50.37
ROC (Joel Greenblatt) (%) -5940.95
OMER's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. OMER: -5940.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMER' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8254.24  Med: -2907.87 Max: -2046.97
Current: -5940.95
-8254.24
-2046.97
Revenue Growth (3Y)(%) 13.10
OMER's Revenue Growth (3Y)(%) is ranked higher than
64% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OMER: 13.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMER' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.75 Max: 13.1
Current: 13.1
0
13.1
EBITDA Growth (3Y)(%) 8.00
OMER's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OMER: 8.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMER' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -9.05 Max: 21.2
Current: 8
0
21.2
EPS Growth (3Y)(%) 7.90
OMER's EPS Growth (3Y)(%) is ranked higher than
65% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. OMER: 7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMER' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -8.9 Max: 19.8
Current: 7.9
0
19.8
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OMER Guru Trades in Q3 2015

Paul Tudor Jones 13,000 sh (New)
Jim Simons 12,593 sh (-90.76%)
» More
Q4 2015

OMER Guru Trades in Q4 2015

Joel Greenblatt 10,225 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2016

OMER Guru Trades in Q1 2016

Joel Greenblatt 19,241 sh (+88.18%)
» More
Q2 2016

OMER Guru Trades in Q2 2016

Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BLCM, NAS:OTIC, NAS:EDIT, NAS:MYOK, NAS:INO, NAS:ATRA, OTCPK:PHMMF, OTCPK:GNFTF, NAS:RGNX, NAS:ITCI, NAS:CERS, NAS:ACRS, NAS:ASND, OTCPK:SNBIF, NAS:RVNC, NAS:ACHN, NAS:VTAE, NAS:PGNX, NAS:CYTK, NAS:CYNA » details
Traded in other countries:3O8.Germany,
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corp was incorporated on June 16, 1994. The Company is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 clinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPARγ program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPARγ agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. The Company is subject to regulate under the U.S. and EU governing regulations.

Ratios

vs
industry
vs
history
P/S 12.12
OMER's P/S is ranked lower than
52% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. OMER: 12.12 )
Ranked among companies with meaningful P/S only.
OMER' s P/S Range Over the Past 10 Years
Min: 8.14  Med: 38.84 Max: 1667.33
Current: 12.12
8.14
1667.33
EV-to-EBIT -8.05
OMER's EV-to-EBIT is ranked lower than
99.99% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 20.32 vs. OMER: -8.05 )
Ranked among companies with meaningful EV-to-EBIT only.
OMER' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.9  Med: -6.1 Max: 0.3
Current: -8.05
-14.9
0.3
EV-to-EBITDA -8.09
OMER's EV-to-EBITDA is ranked lower than
99.99% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 16.98 vs. OMER: -8.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMER' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15  Med: -6.15 Max: 0.3
Current: -8.09
-15
0.3
Current Ratio 3.78
OMER's Current Ratio is ranked lower than
54% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OMER: 3.78 )
Ranked among companies with meaningful Current Ratio only.
OMER' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.12 Max: 6.61
Current: 3.78
0.41
6.61
Quick Ratio 3.69
OMER's Quick Ratio is ranked lower than
52% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. OMER: 3.69 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.01 Max: 6.61
Current: 3.69
0.41
6.61
Days Inventory 305.55
OMER's Days Inventory is ranked lower than
84% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 129.09 vs. OMER: 305.55 )
Ranked among companies with meaningful Days Inventory only.
OMER' s Days Inventory Range Over the Past 10 Years
Min: 182.32  Med: 182.32 Max: 305.55
Current: 305.55
182.32
305.55
Days Sales Outstanding 107.86
OMER's Days Sales Outstanding is ranked lower than
74% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. OMER: 107.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.06  Med: 86.46 Max: 265.45
Current: 107.86
36.06
265.45
Days Payable 1.00
OMER's Days Payable is ranked lower than
97% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.68 vs. OMER: 1.00 )
Ranked among companies with meaningful Days Payable only.
OMER' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 2253.81 Max: 2253.81
Current: 1
1
2253.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.70
OMER's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. OMER: -13.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMER' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -98.1  Med: -12.6 Max: 0
Current: -13.7
-98.1
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.31
OMER's Price/Median PS Value is ranked higher than
88% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OMER: 0.31 )
Ranked among companies with meaningful Price/Median PS Value only.
OMER' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 1.13 Max: 42.72
Current: 0.31
0.31
42.72
Earnings Yield (Greenblatt) (%) -12.37
OMER's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. OMER: -12.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMER' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.39  Med: 381.25 Max: 1464.3
Current: -12.37
-12.39
1464.3

More Statistics

Revenue (TTM) (Mil) $35.39
EPS (TTM) $ -1.72
Beta3.59
Short Percentage of Float26.65%
52-Week Range $7.20 - 16.80
Shares Outstanding (Mil)42.92

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 39 67 139 218
EPS ($) -1.65 -1.29 -0.03 1.01
EPS w/o NRI ($) -1.65 -1.29 -0.03 1.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:OMER

Headlines

Articles On GuruFocus.com
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

More From Other Websites
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Dec 01 2016
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Nov 30 2016
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Nov 30 2016
ETFs with exposure to Omeros Corp. : November 23, 2016 Nov 23 2016
Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial Nov 21 2016
Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial Nov 21 2016
OMEROS CORP Financials Nov 17 2016
Omeros Corp (OMER) in Focus: Stock Jumps 6.4% in Session Nov 15 2016
Edited Transcript of OMER earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 11 2016
ETF’s with exposure to Omeros Corp. : November 11, 2016 Nov 11 2016
Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 10, 2016 Nov 10 2016
Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative... Nov 10 2016
Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative... Nov 10 2016
OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Omeros reports 3Q loss Nov 09 2016
Omeros reports 3Q loss Nov 09 2016
Omeros Corporation Reports Third Quarter 2016 Financial Results Nov 09 2016
OMEROS CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)